Merck (MRK) Molnupiravir Pill Could Change the Fight Against Covid - Bloomberg
Merck Pulls Keytruda for SCLC | LCFA
New Covid Antiviral Pills Offer Hope as Omicron Looms - The New York Times
Merck's Covid-19 Pill Heavily Used So Far Despite Concerns - WSJ
Merck says experimental Covid pill cuts risk of death, hospitalization by 50 percent
Merck to pull carcinogens from top diabetes drugs | News | nny360.com
Merck Closes Deal for Acceleron Pharma, Biggest Biotech Merger of the Year | Barron's
Merck Explores Purchase of Biotech Seagen - WSJ
Merck & Co pulls out of hepatitis C R&D as market shrinks - PMLiVE
Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators' review time only one benefit | Fierce Pharma
Merck pulls Keytruda's FDA nod for third-line stomach cancer | pharmaphorum
Merck's Covid Treatment Pill: What to Know About Molnupiravir - The New York Times
Merck's (MRK) Covid Drug Linked to Viable, Spreading Mutants, Study Says - Bloomberg
FDA authorizes Merck's Covid-19 pill, but stresses its use should be limited
New COVID-19 pills may keep recently diagnosed patients out of hospital, company says - ABC News
Merck's Keytruda Pulled for SCLC as FDA Re-Evaluates Past Accelerated Approvals | BioSpace
